Beigene Ltd
NASDAQ:ONC

Watchlist Manager
Beigene Ltd Logo
Beigene Ltd
NASDAQ:ONC
Watchlist
Price: 288.18 USD -3.39% Market Closed
Market Cap: 401.7B USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one ONC stock under the Base Case scenario is 460.86 USD. Compared to the current market price of 288.18 USD, Beigene Ltd is Undervalued by 37%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ONC Relative Value
Base Case
460.86 USD
Undervaluation 37%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

6.8
P/S
P/S
Price to Sales
6.8
vs History
71
vs Industry
47
Median 3Y
7.7
Median 5Y
8
Industry
7.5
Forward
5.5
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-18.5
Median 5Y
-15.6
Industry
24.2
Forward
381.1
More Details
212.4
P/OCF
P/OCF
Price to OCF
212.4
vs History
10
vs Industry
Median 3Y
-15.1
Median 5Y
-13.3
Industry
20.5
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-12.8
Median 5Y
-12.1
Industry
22.4
More Details
8.3
P/B
P/B
Price to Book Value
8.3
vs History
13
vs Industry
11
Median 3Y
4.8
Median 5Y
4.5
Industry
2.9
More Details
6.4
EV/S
EV/S
Enterprise Value to Sales
6.4
vs History
65
vs Industry
40
Median 3Y
6.8
Median 5Y
7.2
Industry
8
Forward
5.1
More Details
7.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
7.6
vs History
69
vs Industry
41
Median 3Y
8.2
Median 5Y
8.5
Industry
10.2
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-12.3
Median 5Y
-10.8
Industry
5.1
Forward
108.3
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-12.3
Median 5Y
-10.8
Industry
5.3
Forward
420.1
More Details
200.1
EV/OCF
EV/OCF
Enterprise Value to OCF
200.1
vs History
10
vs Industry
Median 3Y
-12.5
Median 5Y
-10.5
Industry
5.8
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-9.8
Median 5Y
-9.2
Industry
4
More Details
9.7
EV/IC
EV/IC
Enterprise Value to IC
9.7
vs History
13
vs Industry
19
Median 3Y
6.8
Median 5Y
6.8
Industry
5.1
More Details

Multiples Across Competitors

ONC Competitors Multiples
Beigene Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
KY
Beigene Ltd
NASDAQ:ONC
204B USD 6.8 -63.3 -85.7 -85.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 059 881.3 -161 881.6 -196 575.9 -194 332.7
US
Abbvie Inc
NYSE:ABBV
349.8B USD 6 94 15.5 22.6
US
Amgen Inc
NASDAQ:AMGN
155.1B USD 4.4 23.4 18.4 18.4
US
Gilead Sciences Inc
NASDAQ:GILD
148.3B USD 5.1 23.5 10.9 15
US
Epizyme Inc
F:EPE
94.1B EUR 2 068.4 -527.8 -574.7 -559.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
93.9B USD 8.2 25.8 18.9 19.8
AU
CSL Ltd
ASX:CSL
127.6B AUD 5.5 30.3 18.5 23.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
59.9B USD 4.2 13.4 12.1 13.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
57.5B USD 23.4 -180.2 -450 -308.9
US
Seagen Inc
F:SGT
39.3B EUR 19.9 -61.1 -65.9 -59.4
P/S Multiple
Revenue Growth P/S to Growth
KY
Beigene Ltd
NASDAQ:ONC
Average P/S: 3 096 548.5
6.8
24%
0.3
FR
Pharnext SCA
OTC:PNEXF
34 059 881.3
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.4
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
5.1
4%
1.3
US
E
Epizyme Inc
F:EPE
2 068.4
N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
8.2
10%
0.8
AU
CSL Ltd
ASX:CSL
5.5
7%
0.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.2
4%
1.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
23.4
31%
0.8
US
S
Seagen Inc
F:SGT
19.9
30%
0.7
P/E Multiple
Earnings Growth PEG
KY
Beigene Ltd
NASDAQ:ONC
Average P/E: 35.1
Negative Multiple: -63.3 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 881.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
94
88%
1.1
US
Amgen Inc
NASDAQ:AMGN
23.4
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
23.5
189%
0.1
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527.8 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.8
N/A N/A
AU
CSL Ltd
ASX:CSL
30.3
16%
1.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.4
7%
1.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -180.2 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.1 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KY
Beigene Ltd
NASDAQ:ONC
Average EV/EBITDA: 15.7
Negative Multiple: -85.7 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 575.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.5
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
18.4
10%
1.8
US
Gilead Sciences Inc
NASDAQ:GILD
10.9
6%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -574.7 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
18.9
17%
1.1
AU
CSL Ltd
ASX:CSL
18.5
11%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.1
9%
1.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -450 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -65.9 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
KY
Beigene Ltd
NASDAQ:ONC
Average EV/EBIT: 18.8
Negative Multiple: -85.7 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 332.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.6
28%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.4
19%
1
US
Gilead Sciences Inc
NASDAQ:GILD
15
12%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -559.4 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
19.8
17%
1.2
AU
CSL Ltd
ASX:CSL
23.2
14%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.6
10%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -308.9 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.4 N/A N/A

See Also

Summary
ONC intrinsic value, competitors valuation, and company profile.
DCF Valuation
ONC stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ONC stock valuation using valuation multiples.
Wall Street Estimates
ONC price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ONC stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 274,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.